



Correction to: Pigment Epithelium-Derived Factor Improves Paracellular Blood–Brain Barrier Integrity in the Normal and Ischemic Mouse Brain

Arina Riabinska^{1,3} · Marietta Zille^{2,4} · Menderes Yusuf Terzi^{1,5} · Ryan Cordell¹ · Melina Nieminen-Kelhä¹ · Jan Klohs^{2,6,7} · Ana Luisa Piña¹

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Correction to: Cellular and Molecular Neurobiology
<https://doi.org/10.1007/s10571-019-00770-9>

The original version of the article unfortunately contained an error in the unit of the protein concentrations under ‘Stereotactic Intraparenchymal Injections’ subsection in ‘Methods’ section.

The unit should be ng/μl instead of ng/ml.

Therefore, the sentence should read as follows:

For the claudin-5 expression study, solutions with the following protein concentrations were prepared: 40 ng/μl VEGF (group VEGF alone), 40 ng/μl VEGF and 40 ng/μl PEDF (group VEGF:PEDF 1:1), and 40 ng/μl VEGF and 80 ng/μl PEDF (group VEGF:PEDF 1:2).

The original article can be found online at <https://doi.org/10.1007/s10571-019-00770-9>.

✉ Ana Luisa Piña
ana-luisa.pina@charite.de

¹ Department of Neurosurgery, Experimental Neurosurgery/BCRT, Charite-Universitätsmedizin Berlin, Campus Mitte, Chariteplatz 1/Virchowweg 21, Aschheim-Zondek-Haus 03-003, 10117 Berlin, Germany

² Department of Experimental Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany

³ Department of Internal Medicine, Medical Clinic I, University Hospital of Cologne, Cologne, Germany

⁴ Institute for Experimental and Clinical Pharmacology and Toxicology, University of Lübeck, Lübeck, Germany

⁵ Department of Medical Biology, Hatay Mustafa Kemal University, Antakya, Hatay, Turkey

⁶ Institute for Biomedical Engineering, ETH and University of Zurich, Zurich, Switzerland

⁷ Neuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland

Accordingly, the caption of Fig. 1 should be as follows:




Fig. 1 The Co-injection of PEDF after VEGF-induced hyperpermeability reduces the paracellular blood–brain barrier disruption. **a** We wanted to confirm that VEGF induces hyperpermeability in the brain. Therefore, we administered intraparenchymal injection of 40 ng/ μ l VEGF or CSF to the brain. VEGF did not significantly induce the transcellular extravasation of Evans Blue (expressed as the fold change to CSF, $n=3$). However, we recognize that the sample size was likely not large enough to show statistical significance. **b** Compared to VEGF alone (40 ng/ μ l), the coadministration of PEDF (40 ng/ μ l) did not change the Evans Blue extravasation ($n=6$). **c**

Shown are representative pictures from the claudin-5 (Cln-5) stained brain samples in mice receiving an intraparenchymal injection of CSF, VEGF, or VEGF + PEDF. Scale bar = 100 μ m. **d** The number of claudin-5-immunoreactive vessels significantly increased after the VEGF + PEDF (40 ng/ μ l VEGF and 40 ng/ μ l PEDF for VEGF:PEDF 1:1, $n=11$; 40 ng/ μ l VEGF and 80 ng/ μ l PEDF for VEGF:PEDF 1:2, $n=9$) compared to the 40 ng/ μ l VEGF-only treatment, indicating an improved paracellular BBB integrity. The data are represented as medians, except for the amount of claudin-5-immunoreactive vessels in VEGF + PEDF 1:2 that is presented as mean $\pm$ SD, $*p < 0.05$